Publishing of Orion Corporation's Interim Report for

ORION CORPORATION     STOCK EXCHANGE RELEASE   8 OCTOBER 2013 at 9:50 A.M. EEST Orion will publish its Interim Report January-September 2013 on Tuesday, 22 October 2013 approximately at 12:00 Finnish time (EEST). The release and related presentation material in Finnish and in English will be available on the Group's homepage at www.orion.fi/en/investors promptly after the publishing. News conference for analysts and media on Tuesday 22 October 2013 at 13:30 EEST A news conference for analysts and media will be held on Tuesday 22 October 2013 at 13:30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will give a brief presentation in English on the financial review. Live webcast and conference call The event can be followed live as a webcast accessible at http://qsb.webcast.fi/o/orion/orion_2013_1022_q3. Questions can be asked also through conference call lines after the result presentation. The conference call ID is 937158 and the phone numbers to participate the conference are: when calling from Finland                +358 (0)9 2313 9201 when calling from the UK                +44 (0)20 7162 0077 when calling from Sweden                +46 (0)8 5052 0110 when calling from the United States        +1 334 323 6201 The full list of country-specific numbers is available at www.orion.fi/en/investors. News conference recordings A recording of the event in English and a recording of the presentation by the President and CEO in Finnish will be available on the Orion website later the same day. Silent period The silent period preceding the publication is ongoing and continues until the disclosure. Orion Corporation Timo Lappalainen Jari Karlson President and CEO CFO Publisher: Orion Corporation www.orion.fi/en Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs. Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki. [HUG#1734224]